THERAPEUTICS, VASCULAR DISEASE
An oral direct factor Xa inhibitor anticoagulant used to prevent deep vein thrombosis and pulmonary embolism after total hip or total knee replacement surgery, and prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Adverse effects Haemorrhage, haematoma formation
Studies supporting rivaroxaban’s efficacy RECORD1 to RECORD4, MAGELLAN, EINSTEIN, ROCKET-AF, ATLAS ACS 2, TIMI 51
It is marketed in the US by Janssen Pharmaceutica.
Other names BAY 59-7939, Xarelto®